Cannabinoids
By Design

Lygos uses a fermentation-based technology to enable the production of highly pure and consistent cannabinoids for consumer and pharmaceutical applications. We are harnessing the power of biology to unlock the therapeutic potential of nature.

Common, Rare, Novel

Products

CBG

CBG

CBC

CBC

CBD

CBD

CBN

CBN

CBGA

CBGA

CBCA

CBCA

CBDA

CBDA

CBDV

CBDV

CBG

CBG

Cannabigerol (CBG) is a non-psychoactive cannabinoid that is believed to have antibacterial, anti-inflammation, antioxidant, and neuroprotective applications. CBG is currently being used in nutritional and cosmetic product applications.

Buy Now
CBC

CBC

Cannabichromene (CBC) is a non-psychoactive cannabinoid, which is produced at low levels by the cannabis plant that is believed to have antioxidant and antiinflammatory properties. CBC has potential applications in pain and skin related health, and has been demonstrated to promote neurogenesis and inhibit tumors and cancers.

Buy Now
CBD

CBD

Cannabidiol (CBD) is a non-psychoactive cannabinoid produced in high abundance by the cannabis and hemp plants. CBD is one of the most well characterized cannabinoids with applications as a therapeutic for epilepsy and other neurological and anxiety disorders.

Buy Now
CBN

CBN

Cannabinol (CBN) is a cannabinoid that is produced from the oxidation or degradation of other cannabinoid compounds, but is found in only small quantities in the plant. Studies have shown that CBN has applications for pain, inflammation and insomnia.

Buy Now
CBGA

CBGA

Cannabigerolic Acid (CBGA) is a non-psychoactive cannabinoid and is considered the “stem cell” of cannabinoids since all pentyl side chain cannabinoids are derived from CBGA. Studies into the effects of CBGA have shown that it has similar anti-inflammatory and anti-anxiety benefits to that of its daughter molecules.

Buy Now
CBCA

CBCA

Cannabichromenic acid (CBCA) is a non-psychoactive cannabinoid that is believed to have applications as an anti-inflammatory, antimicrobial and analgesic compound.

Buy Now
CBDA

CBDA

Cannabidiolic acid (CBDA) is a non-psychoactive cannabinoid and the precursor to CBD. While similar in structure to CBD, studies have shown that this compound has improved anti-nausea and anti-anxiety effects.

Buy Now
CBDV

CBDV

Cannabidivarin (CBDV) is a non-psychoactive cannabinoid produced in low abundance by the cannabis/hemp plant. CBDV is similar in structure to CBD and is being investigated as an anti-seizure and anti-inflammation product.

Buy Now
Leading Capabilities

Services

Bulk Supply

Bulk Supply

Large-scale production with unmatched reliability

Lygos specializes in large-scale production and commercialization of cannabinoids ranging from orders of scale to 10s to 1,000s of kilograms. Our consistency helps our partners plan ahead to eliminate risks of product availability or diminished quality at large scale from various plant supplied sources. We provide dependable wholesale supply solutions for a variety of cannabinoids at unmatched reliability across several geographical areas that are inaccessible by the plant today.

Formulation

Formulation

Unique mixtures for new and existing markets

Lygos’ ability to access a wide variety of cannabinoids enables us to create unique products to address existing and new markets. We work with our partners to formulate specific desired mixtures as powders, liquids or other physical forms. The addition of our materials will help enhance existing properties, working together to do more than any single component.

Custom Synthesis

Custom Synthesis

Full-service design and production

Lygos works with our partners to design and produce plant-based or novel compounds from the bench to commercial scale. Our exclusive cannabinoid production platform supports both plant and non-plant-derived cannabinoids, providing our partners with unique building blocks and significant time and effort savings. Our ability to design unique molecules, especially polyketides, have shown promising applications in both pharmaceutical and nutraceutical applications.

Efficacy

Efficacy

Safety and toxicology expertise

Lygos’ rigorous scientific team possesses extensive understanding of cannabinoids. This allows us to focus not only on manufacturing, but also how the molecules operate and potential benefits of working together within the human endocannabinoid system. Our team of experts has the ability to work with partners in early stage toxicology and efficacy tests, ensuring the right cannabinoid and/or cannabinoid formulation is selected for the right application.

Leading Capabilities

Services

Bulk Supply

Large-scale production with unmatched reliability

Lygos specializes in large-scale production and commercialization of cannabinoids ranging from orders of scale to 10s to 1,000s of kilograms. Our consistency helps our partners plan ahead to eliminate risks of product availability or diminished quality at large scale from various plant supplied sources. We provide dependable wholesale supply solutions for a variety of cannabinoids at unmatched reliability across several geographical areas that are inaccessible by the plant today.

Formulation

Unique mixtures for new and existing markets

Lygos’ ability to access a wide variety of cannabinoids enables us to create unique products to address existing and new markets. We work with our partners to formulate specific desired mixtures as powders, liquids or other physical forms. The addition of our materials will help enhance existing properties, working together to do more than any single component.

Custom Synthesis

Full-service design and production

Lygos works with our partners to design and produce plant-based or novel compounds from the bench to commercial scale. Our exclusive cannabinoid production platform supports both plant and non-plant-derived cannabinoids, providing our partners with unique building blocks and significant time and effort savings. Our ability to design unique molecules, especially polyketides, have shown promising applications in both pharmaceutical and nutraceutical applications.

Efficacy

Safety and toxicology expertise

Lygos’ rigorous scientific team possesses extensive understanding of cannabinoids. This allows us to focus not only on manufacturing, but also how the molecules operate and potential benefits of working together within the human endocannabinoid system. Our team of experts has the ability to work with partners in early stage toxicology and efficacy tests, ensuring the right cannabinoid and/or cannabinoid formulation is selected for the right application.

Safe, Sustainable, Cost-Effective

Platform

At the core of Lygos’ cannabinoid discovery and development platform is our Bio-Innovation Engine. The efficiency and modularity built into the platform allows for large-scale production of different cannabinoids, even those that are not easily accessible through traditional agricultural means. We strive to deliver our naturally derived cannabinoids at costs that enable everyday consumer products and novel compounds for the next generation of cannabinoid-inspired pharmaceutical care.

Learn more about our platform

Contact Us

FAQs

Lygos uses its proprietary fermentation and synthetic bioengineering process to produce any common, rare, or novel cannabinoid and cannabinoid-based product of interest in an environmentally safe, sustainable, and cost-effective manner. This is accomplished by modifying baker’s yeast (Saccharomyces cerevisiae) to produce compounds in the same way that the cannabis plant does. By controlling this process at the molecular level, we can obtain highly efficient production of cannabinoids. Since no plants are used in the process we do not require large amounts of land, water, energy, fertilizers, or pesticides.
Lygos’ process can be scaled to deliver cannabinoids that can meet large scale commercial needs, starting with supply of 10s to 100s of kilograms.
Lygos provides ultra-high purity cannabinoids that are free from contamination of other cannabinoids, terpenes or other plant compounds. They also adhere to ICH guidelines or other specifications provided by our customers. Cannabinoids produced from agricultural production occur simultaneously and are structurally similar to each other, making the separation of these compounds difficult at scale. As a result, the impurity profiles of cannabinoids that are isolated from the plant often contain other cannabinoids. Lygos carefully controls the production of only a single cannabinoid, enabling high purity production of cannabinoids >99%, as well as a consistent impurity profile that is void of active cannabinoids or other compounds.
Lygos uses its proprietary fermentation and synthetic bioengineering process in a repeatable and scalable manner. In leveraging this process, our products exhibit highly reproducible profiles that maintain consistent odorless and colorless results. Further, the high performance platform can meet many common or unique specification profiles to match a range of potential needs.
Lygos’ production platform is similar to other biosynthetic production platforms that have been used to produce active pharmaceutical ingredients (APIs) in the pharmaceutical industry. The highly controlled process can be implemented so that it conforms with GMP or FDA guidelines.
The cannabinoids produced from Lygos’ platform can be mixed into various formulations in the same way as plant derived cannabinoids. Lygos can also help with formulating and mixing, and on demand, we can deliver oil based, aqueous salt, ester forms or other related phases of interest to aid in formulation requirements.

Partner with Us

Lygos is interested in forming strategic partnerships that will enable us to deliver new cannabinoid-enabled products for high-growth consumer market segments. Contact us today to learn more about how we can work together.

About Lygos CBx

Lygos CBx is a direct result of the recent Librede acquisition and integration of additional Lygos technology advances. Lygos is a leading provider of sustainable specialty ingredients that deliver high-value performance without environmental toxicity.

Partner with Us

Lygos is interested in forming strategic partnerships that will enable us to deliver new cannabinoid-enabled products for high-growth consumer market segments. Contact us today to learn more about how we can work together.

About Lygos CBx

Lygos CBx is a direct result of the recent Librede acquisition and integration of additional Lygos technology advances. Lygos is a leading provider of sustainable specialty ingredients that deliver high-value performance without environmental toxicity.